Glucocorticoid-induced osteoporosis
Conditions
Interventions
Once weekly subcutaneous injection of teriparatide acetate
Weekly oral administration of 35 mg alendronate with approximately 180 mL of water on rising in the morning.
Sponsors
Glucocorticoid-induced osteoporosis research group
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Patients who have been taking or are scheduled to take oral steroid at a dose equivalent to 5 mg/day of prednisolone or higher for at least 3 months 2) Patients aged 20 years or older
Exclusion criteria
Exclusion criteria: 1) Patients who previously used bisphosphonate. However, use for up to 2 weeks, 6 months or more before the enrollment is allowed. 2) Patients who have used Teribone or Forteo in the past. 3) Patients for who have contraindications of teriparatide and alendronate. 4) Patients who have 3 or more lumbar vertebral bodies could not be evaluated in DXA. 5) Patients who have used denosumab within the 6 months before enrollment. 6) Patients who were considered as inappropriate for the study by physician.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Changes of lumbar bone mineral density | — |
Secondary
| Measure | Time frame |
|---|---|
| - Incidence of vertebral fractures - Incidence of non-vertebral fractures - Changes of bone turnover markers - Pain, QOL - Adverse events and adverse drug reactions | — |
Countries
Japan
Outcome results
None listed